Abstract：
Numerous clinical trials involving natural products have been conducted to observe cognitive performances and biomarkers in Alzheimer\'s Disease (AD) patients. However, to date, no natural-based drugs have been approved by the FDA as treatments for AD. In this review, natural product-based compounds that were tested in clinical trials from 2011 to 2023, registered at www.clinicaltrials.gov were reviewed. Thirteen compounds, encompassing 7 different mechanisms of action were covered. Several observations were deduced, which are: i) several compounds showed cognitive improvement, but these improvements may not extend to AD, ii) compounds that are endogenous to the human body showed better outcomes, and iii) Docosahexaenoic acid (DHA) and cerebrolysin had the most potential as AD drugs among the 13 compounds. Based on the current findings, natural products may be more suitable as a supplement than AD drugs in most cases. However, the studies covered here were conducted in a relatively short amount of time, where compounds acting on AD pathways may take time to show any effect. Given the diverse pathways that these natural products are involved in, they may potentially produce synergistic effects that would be beneficial in treating AD. Additionally, natural products benefit from both physicochemical properties being in more favorable ranges and active transport playing a more significant role than it does for synthetic compounds.
摘要：
已经进行了许多涉及天然产物的临床试验，以观察阿尔茨海默病（AD）患者的认知表现和生物标志物。然而,到目前为止,FDA尚未批准天然药物作为AD的治疗方法.在这次审查中,2011年至2023年在临床试验中测试的基于天然产品的化合物，在www上注册。对临床试验进行了综述。13种化合物,涵盖了7种不同的作用机制。推断了一些观察结果，它们是：i）几种化合物显示出认知改善，但这些改善可能不会延伸到AD，ii)对人体内源性的化合物显示出更好的结果，和iii）在13种化合物中，二十二碳六烯酸（DHA）和脑活素作为AD药物的潜力最大。根据目前的调查结果,在大多数情况下，天然产品可能比AD药物更适合作为补充剂。然而,本文涵盖的研究是在相对较短的时间内进行的,在这种情况下,作用于AD途径的化合物可能需要时间才能显示出任何效果.鉴于这些天然产物涉及的不同途径，它们可能潜在地产生协同效应,这将有益于治疗AD.此外,天然产物受益于物理化学性质在更有利的范围内和活性运输发挥更重要的作用比它对合成化合物。
